Authors
Latest:
Future Treatment Approaches for HCCClosing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.
Latest:
Baptist Health Adopts Innovative AI Solutions, Cutting-Edge Research to Address Complexities of CareThe rapid progress in oncology, along with complex cases and rising costs, presents challenges in delivering high-quality cancer care.
Latest:
Steroid-Refractory cGvHD: Emerging Treatment OptionsThis segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the potential benefits, risks, and optimal patient selection for these novel therapies.
Latest:
Boland Discusses Melanoma Treatment UpdatesGenevieve Boland, MD, PhD, discusses the latest updates to the melanoma treatment landscape.
Latest:
Bal on Targeting GPRC5D in R/R Multiple MyelomaSusan Bal, MD, discusses novel targets for relapsed/refractory multiple myeloma at the 2023 Annual Meeting.
Latest:
Novel Approaches in MCL Treatment and Predictive InsightsJulie Chang, MD, discusses the reasoning behind the development of a minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma.
Latest:
Improving Access to Bone Marrow Transplant and Cellular TherapiesStem cell treatments offer hope for a variety of conditions. However, access to these potentially life-altering procedures is often hampered by social factors such as socioeconomic status, race, cultural background, and geographic location.
Latest:
Ra-223 Demonstrates Safety, Efficacy in Managing Bone Metastases in Prostate CancerPatients diagnosed with bone metastatic, castration-resistant prostate cancer and treated with radium-223 showed lower incidences of treatment-related adverse events or treatment discontinuation, particularly when used in the front-line setting.
Latest:
Neoadjuvant Blockade Demonstrates Significant Clinical Activity in UPSChristina L. Roland, MD, PhD, discusses the preliminary results of neoadjuvant checkpoint blockade—nivolumab or nivolumab plus ipilimumab—in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Latest:
Screening for SCLC Can Change Overall PrognosisThe push for more screening of patients with a history of smoking is providing oncologists the ability to catch small cell lung cancers earlier and potentially change the prognosis of the disease.
Latest:
Growing Use of Bispecifics for the Treatment of Multiple MyelomaGeorge Nahas, DO, discusses ongoing research that may shape the future treatment landscape of multiple myeloma.
Latest:
Examining Changes in the Multiple Myeloma Treatment LandscapeJeffrey R. Schriber, MD, FRCP, discusses some of the available treatment options for patients with multiple myeloma and how the treatment landscape has evolved over time.
Latest:
PTCy Levels the Playing Field for Unrelated Donor Hematopoietic Cell TransplantsJeff Auletta, MD, discusses findings from a study evaluationg posttransplant cyclophosphamide in unmatched stem cell transplants.
Latest:
The Targeted Pulse: ODAC Deems MRD for End Point in MM, A Deep Dive Into Amivantamab in NSCLC, and MoreIn this weekly recap ODAC endorses MRD for accelerated myeloma trial approval, research delves into ovarian cancer trends in Asian American populations, amivantamab’s variable efficacy in NSCLC, and more.
Latest:
New Horizons in the Management of MDSFuture perspective on the growing treatment landscape for patients with MDS.
Latest:
10 Years in CLL: Top Advances From 2012-2022The past decade has seen the FDA approve a handful of new targeted therapies for chronic lymphocytic leukemia that are prompting a move toward chemotherapy-free treatment of the disease.
Latest:
Future Directions in Graft Versus Host DiseaseClosing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.
Latest:
Pembrolizumab Plus Chemotherapy Show Efficacy for TNBC in KEYNOTE-355Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Latest:
Differentiating Pseudoprogression From Hyperprogression in Patients Treated With ImmunotherapiesAdvances in the field have also led to the recognition of other clinical challenges, including unforeseen observations and complications associated with choosing the sequencing of appropriate therapeutic interventions as well as the management of drug-related complications.
Latest:
Ibrutinib Plus Venetoclax May Be an Effective Treatment for Previously Untreated WMFast and durable response were seen in patients with Waldenström Macroglobulinemia who received the combination of ibrutinib and venetoclax.
Latest:
Discussing the FOHAIC-1 Study for Patients With HCCMing Zhao, MD, explains the background of the FOHAIC-1 study.
Latest:
Breast Cancer Awareness Month: What to Know for Different Types of Breast CancerFor Breast Cancer Awareness Month Kristina Mirabeau-Beale, mD, MPH, and Bridget Koontz, MD, discuss the different types of breast cancer that clinicians need to be aware of.
Latest:
Case 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast CancerHeather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.
Latest:
Behind the CheckMate-77T Trial of a Nivolumab-Based Regimen in NSCLCTina Cascone, MD, PhD, discusses the CheckMate-77T trial of perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab for the treatment of patients with stage IIA to IIIB non-small cell lung cancer.
Latest:
Long-Term Management of Patients with P53 AberrationsTreatment approaches to address mutations or deletions of chromosome 17p are needed due to the surfacing of point mutations, including TP53 aberrations in chronic lymphocytic leukemia.
